Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00994916
Expanded Access Status : Available
First Posted : October 14, 2009
Last Update Posted : October 9, 2018
Jacobus Pharmaceutical
Information provided by (Responsible Party):
David Lacomis, MD, University of Pittsburgh

Brief Summary:
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Condition or disease Intervention/treatment
Lambert-Eaton Myasthenic Syndrome Drug: 3,4 diaminopyridine

Detailed Description:

Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained.

The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board.

The investigator has a hold on enrolling new subjects.

Study Type : Expanded Access
Official Title: Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Intervention Details:
  • Drug: 3,4 diaminopyridine
    3,4 diaminopyridine up to 80 mg daily in divided doses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Diagnosis of LEMS
  2. Over 18 years old
  3. Medically stable
  4. If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study

Exclusion Criteria:

  1. Known sensitivity to 3,4 DAP
  2. History of past or current seizures
  3. History of severe asthma
  4. Believed by the investigator to be unable to comply with the protocol
  5. Unable to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00994916

Contact: David Lacomis, MD 412-647-1706

Sponsors and Collaborators
David Lacomis, MD
Jacobus Pharmaceutical

Responsible Party: David Lacomis, MD, Professor of Neurology and Pathology, University of Pittsburgh Identifier: NCT00994916     History of Changes
Other Study ID Numbers: IRB0410047
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: October 2018

Keywords provided by David Lacomis, MD, University of Pittsburgh:
Lambert-Eaton myasthenic syndrome
3,4 diaminopyridine

Additional relevant MeSH terms:
Lambert-Eaton Myasthenic Syndrome
Pathologic Processes
Paraneoplastic Syndromes, Nervous System
Nervous System Neoplasms
Neoplasms by Site
Paraneoplastic Syndromes
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action